ANV 600
Alternative Names: ANV-600Latest Information Update: 23 Jul 2024
At a glance
- Originator Anaveon
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies; Interleukins; Recombinant fusion proteins
- Mechanism of Action Immunostimulants; Interleukin 2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 01 Jul 2024 Phase-I/II clinical trials in Solid tumours (Combination therapy, Late-stage disease, Inoperable/Unresectable, Recurrent, Second-line therapy or greater, Metastatic disease) in Switzerland (IV) (NCT06470763)
- 01 Jul 2024 Phase-I/II clinical trials in Solid tumours (Monotherapy, Late-stage disease, Inoperable/Unresectable, Metastatic disease, Second-line therapy or greater, Recurrent) in Switzerland (IV) (NCT06470763)
- 29 May 2024 US FDA approves IND application for ANV 600 in Solid tumours (Parenteral)